Market Trends of Protein Characterization And Quantification Industry
The Mass Spectrometry Instruments Segment is Expected to Witness Significant Growth During the Forecast Period
A mass spectrometer is an instrument that generates ions and then sorts them based on their mass-to-charge (m/z) ratio. Its key components comprise an ion source, a mass analyzer, a detector, and a vacuum system.
Mass spectrometry plays a pivotal role in both characterizing and quantifying proteins. It precisely measures protein and peptide masses, identifies post-translational alterations, examines protein assemblies, and gauges protein levels in intricate mixtures. Mass spectrometry unveils intricate details about protein structures and concentrations by ionizing proteins and segregating ions by their mass-to-charge ratio.
Various research studies were conducted to understand the application of tandem mass spectrometry in protein analysis for biomedical research. For instance, according to an article published by Molecules in April 2022, tandem mass spectrometry methods have proven effective in clinical protein characterization and identification research. They are utilized for qualitative and quantitative bioanalysis of proteins and peptides, including their post-translational modifications (PTMs) and protein-protein interactions (PPIs), across a spectrum of biological samples.
Additionally, advancements in mass spectrometry techniques are facilitating a shift from targeted to untargeted proteomic approaches. This transition is driving the emergence of new omics fields, notably PTM-omics and PPI-omics. These developments are pivotal in enhancing the comprehension of normal and pathological cell states and disease mechanisms. Thus, the rising application and advancements in mass spectrometry techniques and instruments are expected to fuel the adoption of mass spectrometry in studying protein characterization and quantification. This, in turn, is anticipated to augment the segment growth during the forecast period.
Further, a study published in PLOS Biology in April 2022 emphasized the pivotal role of mass spectrometry in quantitatively studying cardiac proteins. It highlighted how mass spectrometry allows for a detailed assessment of protein levels in different cardiac chambers, facilitating comparisons between human and model organism's cardiac protein profiles. This research underscores the significant potential of mass spectrometry in quantifying proteins, particularly in its applications to disease research, hence anticipated to bolster the segment's growth during the forecast period.
Moreover, the rising number of product launches by the key players is expected to fuel the availability of advanced mass spectrometry systems in the market, propelling the segment's growth. For instance, in June 2023, Bruker Corporation launched a new timsTOF Ultra mass spectrometer that can identify over 55K peptides that map into 5000 protein groups at the single-cell level of 0.125 ng protein loading, at 1% FDR and over 4800 protein groups quantified at CVs of <20%.
Therefore, owing to the rising number of research studies on using mass spectrometry in proteomics, advancements in mass spectrometry techniques, and new product launches, the studied segment is expected to grow during the forecast period.
North America is Expected to Witness Significant Growth During the Forecast Period
North America is expected to witness significant growth during the forecast period, owing to the high prevalence of chronic diseases, increasing demand for biologics, government funding for proteomics, and technological advancements in protein characterization and quantification systems. In addition, the presence of key players and their growing strategic activities are expected to boost the market's growth during the forecast period.
The increasing prevalence of cancer among the population raises the demand for effective biologics, which require accurate diagnosis and research of the proteins involved in the disease for developing personalized medicines. This propels the demand for systems that help accurately identify and quantify proteins, propelling the growth of the studied market. For instance, according to the 2024 data published by the American Cancer Society, over 2.1 million people in the United States are expected to be diagnosed with cancer in 2024, compared to 1.9 million people in 2023. Thus, the expected increase in cancer cases is anticipated to boost the demand for detecting and isolating a protein, thereby contributing to the market's growth.
Moreover, data released by the Canadian Cancer Society in November 2022 revealed that Canada experienced over 233,900 new cancer diagnoses in 2022. This surge in cancer cases fuels an increasing demand for gene and monoclonal antibody therapies that are particularly used in the treatment of cancer, rare diseases, and other disorders. Hence, this is expected to drive the market's growth during the forecast period.
Additionally, the market players' key developments are expected to drive the region's growth. For instance, in January 2024, Alamar Biosciences launched the ARGO HT System, which is designed for effortless, high-sensitivity protein analysis in biofluids. The ARGO HT System streamlines NULISA assays, requiring under 30 minutes of hands-on time, significantly reducing the variability inherent in manual assays. This enhances efficiency and liberates researchers' time. The company aims to provide advanced protein analysis through this launch, enhancing sensitivity and multiplexing capabilities. This is expected to aid in identifying crucial biomarkers pivotal in disease advancement and treatment efficacy.
Similarly, in January 2023, Bio-Techne Corporation introduced the ProteinSimple-branded MauriceFlex, a novel system that not only facilitates protein charge variant fractionation but also conducts routine cIEF and CE-SDS assays. This unique offering significantly enhances protein characterization workflows. With the MauriceFlex, users can now perform cIEF-based fractionation on the same day, eliminating the traditional requirements of method development, separate fractionation steps, and the need for data alignment with ion-exchange chromatography (IEX) or alternative methods.
Therefore, owing to the factors above, such as the high burden of cancer and new product launches by the key players, the studied market is anticipated to grow in North America during the forecast period.
